the everyone. Thanks, productive for a or IgGX-Related our results LEAD our X XmAbXXXX. Phase was XXXX from encouraging program good IgGX-RD; Josh, stage technology Xencor. and antibody These a in XmAbXXXX clinical our of We for X engineering Phase XmAb patients we with by our disease we drug from afternoon, and administered year research range for deliver life positive and us to data reported of demonstrate oncology specific expanded announced severe pipeline; threatening accomplishments candidates subcutaneously potential trial busy a XXXX, diseases. position of and new a
biology is specifically of of previously domain Now plug our small the base and improved natural creating XmAb traditional Fc performance. functions of to opens The changes bispecific doors engineering antibody; any half-life, inaccessible an to and platform. us domain allows small have to it's play or structure, antibody our Fc making Xencor's to nature the to antibody we've structural created By antibody approach to structure, nearly can potency, suite XmAb the or we core engineer therapeutics and its improve along antibodies. of
significance partnerships nature also play capital our Xencor while enables requiring programs to that rapidly clinical pipeline, us without and more resources. plug this expand attracting and Importantly, derive
program targeting gastrointestinal solid GIST includes and specific bispecific tumors stromal in in advanced have by or This first -- this our for neuroendocrine thread newest development tumors clinical program partners. month earlier our first trial in XXXXX. Now, and tumors. is our we candidate. We currently X Phase programs program antibody XmAbXXXXX, This internally clinical XX with initiated XmAb based oncology a our
data data AML trials with development. XmAbXXXX X initial XXXXX key from readouts these we our Phase the we XmAbXXXX will XXXXX benefit independently including readout, insights Systemic data X expressing studies, us and Together program top-line malignancies from the enable across over our XXXX, bispecific data make and of into to three portfolio, informed our our expect advance important other SLE, trial Lupus or development programs and to advanced readouts data respectively. B-Cell Now, Erythematosus IgGX-RD for of Phase our XmAb CDXXX and and clinical which provide malignancies milestones programs look decisions to several in most of or internal late-stage as from in
Now we development efforts. our expand parallel, will ongoing in continue to
a XXXX we you second As X year. trial, the patients on of evaluating to half trial IgGX-RD our initiate Phase X Phase the this with expect in know, based of from promising results in
XXXXX bispecific We Investigation New Drug also later applications PDX a antibody expect checkpoints I advanced targeting That's tumor our activator. a to or XmAbXXXXX We and of X the file year. XmAbXXXXX two plan say activators and T-cell Phase CTLAX. bispecific microenvironment this trial IND TME to additional most initiate for
strong gamma to than and currently represent function. rationale of inhibits for evaluating target of variable and domain high into with a B-cell our specifics We're effort, clinical and I'll indications: both our which our CDXX two XXXX receptor that unmet immune demand XmAb is antibody its with of the starting Fc with uses monoclonal have pre-clinical areas B-cell XXXX targets SLE IgGX-RD need. in Now RIIb get that a critically inhibition XmAbXXXX. first-in-class and Fc inhibitor
required achieved at study American X in IgGX-RD at responder safety in and Notably evaluate trial and to reduction from in their patients the XX Now This completed point X least index College in XXX. designed study end of the or Phase November the Day efficacy none ACR corticosteroids of our on primary the IgGX-RD. with Rheumatology of XXXX safety presented we the was IgGX-RD. data of point XX XX-week month two. XX all Meeting in positive patients Annual of after the
of IgGX-RD months. these two eight of remission disease as zero by use Now achieved corticosteroids designed no XX% after patients and or an
patients, of achieved two XX% of than weeks. a two a IgGX-RD responder scores to less Across day index responder or XX equal IgGX-RD all or on X decrease or achieved four equal greater index, within other the their most to Now than in XX XXX.
safe and XXXX continues in sorry; well weeks. an decrease error X IgGX-RD within least additionally made to there, Now oh a responder -- two I I'm their index, of tolerated at be most
XXXX IgGX-RD. be well is of the Now patients these development on all moderate. tolerated, there related to safe mild Based and continue drug we forward with created to believe additionally in continued events adverse with XXXX or is a path results,
development Now a disease appropriate most and because RD no authorities regulatory therapeutic for been with X regulatory is design engaging precedence newly with defined we've no approval to pathway, options IgGX program. Phase
last approximately a randomized U.S. FDA the X X IgGX-RD. the designed to double-blinded patients with study standard Phase XXXX of evaluate we've End Phase of year of an meeting XXX in XXX addition with care to placebo-controlled Following to
initiate to study the expect We second in half this this of year.
We regarding European this also early year. advice in see Agency drop this Medicines intend in to scientific
from received EMA drug we year be additional January, go product for in from with IgGX-RD received Now the the the designation can FDA. last orphan designation in to we what along XXXX
muscular SLE evaluate multi-dose from in disease, SLE. our the disease and uses medication. separately patients trial this progress to symmetric a maintain absence improvement to short So the of in patients of And of design placebo-controlled IgGX the the novel XXXX time top-line enrollment related a in This shorter expect SLE quarter trial. to fewer end, immunosuppressive we allow fourth XXX ability that steroids activity after trial us effective of core we completed the to approximately to to believe we randomized with in XXXX this continue year. in and SLE trial of December data assess and XXXX with to endpoint standard compared To will in report design double-blind
Now to our pipeline. bispecific I will oncology pivot
Our a antigen scalpels native of two binding Fc preserving which properties a demands. The more molecule can while different bind domain or bispecifics created multiple are novel to our antibodies. important built provide of single that for on targets simultaneously robust we results
antibodies that T-cells antigen tumor Our lead programs domain the cells. cytotoxic a of domain at killing site binding the potent T-cell a and by being domain, work They are bispecific malignant activating for T-cell tumor binding CDX. the the contain highly tumor-targeted
can our of balance tune us allow potency reduction activity to bispecifics that to anti-tumor from activation. with the importantly toxicity their result Now a of immune format the T-Cell
to on the CDXXX tumors Phase expressing treatment treatment X partner of malignancies for of plan year. other and for time the and B-cell data AML late pending XmAbXXXXX initial of from with studies our our Now Novartis, the we alignment this announce XmAbXXXXX
to As provide of after a a treatment tolerated are and both assessment of and and designed trials reminder, to the tolerability evaluate preliminary maximum to the infusions subsequent first activity. anti-tumor the safety determine dose
for the X we and bispecific Now of start our XmAbXXXXX. of the escalation SSTRX GIST. neuroendocrine as or antibody advanced of receptor recently X XXXXX somatostat an is dosed first mentioned I CDX today's developing study dose in we're at that by patient Phase call, tumors treatment the
safety on activity. After trial enroll to trial collect immunogenicity just tolerated and to anti-tumor expansion evaluate and efficacy. pharmacokinetics safe dose, tolerability, the of patients X a Phase assist is cohorts safety Our tumor maximum or Phase recommended separate termination this in X designed and in will of neuroendocrine preliminary dose to signs and potential additional data
initial report to expect We in data XXXX.
of our I should a tumor wave targets that To XXXXX, drug agonist. Now eliminate engage for pipeline XXXXX, as us multiple checkpoints They activation expanding environment bispecific antibodies to potential beyond suite of these improve to and have bispecific macro activators TME it bispecifics T-Cell need target. activators specific the T-Cell to a we oncology development. TME are say or of build CDX four against for we multiple XXXXX, build expecting three -- the and are each suite the next a simultaneously at to such the represent combination therapies selectivity our the
this to TME molecules next combinations in activation for of bispecific for T-Cell will activation test will which approach enable best the targets a of each us Now of cancer. these distinct select of wave
microenvironment, with XmAbXXXXX or the Annual targeting November indications. multiple antibodies our development two from at preclinical Both bispecific for in past Now this by CTLA-X posters or and bispecific. the tumor PD-X oncology are bispecific, data presented Citi PD-X XmAbXXXXX we IcO of by Meeting
these alone. superior antigens T-Cell are the tolerated Further that in target antibody selective anti-PD-X mind their for cynomolgus activation Now the antibodies both cells with pharmacokinetics pairs well like antibodies of to monkeys. both compared is and
activator to therapy achieve to triple highly Vivo and anti-PD-X active combine designed TME is is active with blockade. checkpoint third Our XmAbXXXXX also in
XXXXX for XXXXX XXXX trials X have trial We to Phase planned in XXXX. a in and XmAbXXXX evaluating and initiate
our an addition the pipeline receptor Fc XXXXX our or XmAb is candidate to domain. header IL-XX, dimmer our is Now plug-and-play alpha complex IL-XX fused to latest XmAbXXXXX. TME
alpha receptor receptor targeting complex. favors stable T-Cells. use to scaffle IL-XX that We IL-X complexes a target ligand our create Fc IL, called receptor receptor CDXXX XmAb CDXXX Now highly stable or regulatory also naturally beta, without
XmAb our I for T-Cell engineering that data expansion and is American Cancer the for activation say, XXXXX extent half-life. bispecific the preclinical achieved for receptor Annual contains domain XXXXX Meeting we activation longer Now modulated plan Fc by at should designed technology our Research detailed create to in CDXXX or the alpha Association IL-XX to sustained We April. which complex present
Now touch that domain to targeting reduce differentiates XXXX targets first-in-class by IgE on I through will our immune levels. mechanisms action works XmAb RXB IgE monoclonal from that with Fc targets Gamma three briefly uses what of and therapies. our Fc approved variable domain. IgE inhibitor B-Cells targeting its XmAbXXXX distinct That's
free it's First, suppresses clearance IgE it rapid circulation. plasma from it differentiation to IgE-producing signaling, sequesters last, into B-cell block of enables cells, IgE IgE the and next
patients Phase the disease for could with offer currently a in allergic of seeking we development November, Now data of are our standard administration partner. subcutaneous we XXXX and based or asthma on improvement believe care reported X subcutaneous
a that partnerships our expanding rights take our additional technology, for work our to our pipeline. shots -- we tried we allowing that's of to partnerships, our XmAb look R&D I'll our core particularly the partnering is Using ourselves we little the on for Next promising part really programs go quick attaining licensing a pursuing or assets. or focus we us as our for most resources can programs on continue on no update do aren't strategy Critically commercial pipeline. own in of
are clinical proprietary XmAb two companies discovered in Xencor NIH development that pharmaceutical domains. rely drug advancing six There on including and eight Phase programs such currently X Fc currently our or either candidate in are studies. Now, at
extent The QX expected Alexion two filings is this first and XXXX our half-life. of Data inhibitor in for regulatory from Alexion expected XXXX technology uses of year. X long these trials next-generation a Phase CX of year this is two are with later that advancing
combination November with these programs. in In a readouts both of breakthrough which trial second and with in also XmAbXXXX DLBCL these XXXX being Morphosys. diffused The the relapsing in in MORXXX X large Bendamustine. lymphoma await is refractory relapsed of is refractory B-Cell by in therapy data received they combination We they Phase developed designation from are Lenalidomide eagerly
much are Xencor. December technology myeloma. partnerships CDX T-Cell Now CDXX XmAb bispecific submitted targeting bispecific for our bispecific IND an for returning then more for and Amgen CDX uses announced AMG and novel at application we in antibody XXX and produced recent binding CDXX multiple our XXX domains which
IND is filing which this payment reflected triggered Now million in financials. a our $XX milestone
quick we a currently into to team stages the we very board of and insights on and welcomed experience his EVP BioMarin is December, our Human development Finally comment to Richard Rich In look forward commercial into directors. Ranieri much here. from Resources building biotech of progress companies later we organizations and research of brings substantial of development. as
results. financial call to the Now and over with to will I our review quarter fourth XXXX John full-year that, John? turn
